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Background: The ongoing outbreak of the recently 
emerged novel coronavirus (2019-nCoV) poses a chal-
lenge for public health laboratories as virus isolates 
are unavailable while there is growing evidence that 
the outbreak is more widespread than initially thought, 
and international spread through travellers does 
already occur. Aim: We aimed to develop and deploy 
robust diagnostic methodology for use in public health 
laboratory settings without having virus material avail-
able. Methods: Here we present a validated diagnostic 
workflow for 2019-nCoV, its design relying on close 
genetic relatedness of 2019-nCoV with SARS coronavi-
rus, making use of synthetic nucleic acid technology. 
Results: The workflow reliably detects 2019-nCoV, 
and further discriminates 2019-nCoV from SARS-CoV. 
Through coordination between academic and public 
laboratories, we confirmed assay exclusivity based 
on 297 original clinical specimens containing a full 
spectrum of human respiratory viruses. Control mate-
rial is made available through European Virus Archive 
– Global (EVAg), a European Union infrastructure pro-
ject. Conclusion: The present study demonstrates the 
enormous response capacity achieved through coordi-
nation of academic and public laboratories in national 
and European research networks.
Introduction
According to the World Health Organization (WHO), the 
WHO China Country Office was informed of cases of 
pneumonia of unknown aetiology in Wuhan City, Hubei 
Province, on 31 December 2019 [1]. A novel coronavirus 
currently termed 2019-nCoV was officially announced 
as the causative agent by Chinese authorities on 
7 January. A viral genome sequence was released 
for immediate public health support via the com-
munity online resource  virological.org  on 10 January 
(Wuhan-Hu-1, GenBank accession number MN908947 
[2]), followed by four other genomes deposited on 12 
January in the viral sequence database curated by the 
Global Initiative on Sharing All Influenza Data (GISAID). 
The genome sequences suggest presence of a virus 
closely related to the members of a viral species termed 
severe acute respiratory syndrome (SARS)-related CoV, 
a species defined by the agent of the 2002/03 outbreak 
of SARS in humans [3,4]. The species also comprises a 
large number of viruses mostly detected in rhinolophid 
bats in Asia and Europe.
As at 20 January 2019, 282 laboratory-confirmed 
human cases have been notified to WHO [5]. Confirmed 
cases in travellers from Wuhan were announced on 13 
and 17 January in Thailand as well as on 15 January in 
Japan and 19 January in Korea. The extent of human-
to-human transmission of 2019-nCoV is unclear at the 
time of writing of this report but there is evidence of 
some human-to-human transmission.
Among the foremost priorities to facilitate public health 
interventions is reliable laboratory diagnosis. In acute 
respiratory infection, RT-PCR is routinely used to detect 
causative viruses from respiratory secretions. We have 
previously demonstrated the feasibility of introducing 
robust detection technology based on real-time RT-PCR 
in public health laboratories during international 
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health emergencies by coordination between public 
and academic laboratories [6-12]. In all of these situ-
ations, virus isolates were available as the primary 
substrate for establishing and controlling assays and 
assay performance.
In the present case of 2019-nCoV, virus isolates or 
samples from infected patients have so far not become 
available to the international public health community. 
We report here on the establishment and validation 
of a diagnostic workflow for 2019-nCoV screening and 
specific confirmation, designed in absence of available 
virus isolates or original patient specimens. Design 
and validation were enabled by the close genetic relat-
edness to the 2003 SARS-CoV, and aided by the use of 
synthetic nucleic acid technology.
Methods
Clinical samples and coronavirus cell culture 
supernatants for initial assay evaluation
Cell culture supernatants containing typed coronavi-
ruses and other respiratory viruses were provided by 
Charité and University of Hong Kong research labo-
ratories. Respiratory samples were obtained during 
2019 from patients hospitalised at Charité medical 
centre and tested by the NxTAG respiratory pathogen 
panel (Luminex, S´Hertogenbosch, The Netherlands) 
or in cases of MERS-CoV by the MERS-CoV upE 
assay as published before [10]. Additional samples 
were selected from biobanks at the Rijksinstituut 
voor Volksgezondheid en Milieu (RIVM), Bilthoven, 
at Erasmus University Medical Center, Rotterdam, 
at Public Health England (PHE), London, and at the 
University of Hong Kong. Samples from all collections 
comprised sputum as well as nose and throat swabs 
with or without viral transport medium.
Faecal samples containing bat-derived SARS-related 
CoV samples (identified by GenBank accession 
numbers) were tested: KC633203, Betacoronavirus 
BtCoV/Rhi_eur/BB98–98/BGR/2008; KC633204, 
Betacoronavirus BtCoV/Rhi_eur/BB98–92/BGR/2008; 
KC633201, Betacoronavirus BtCoV/Rhi_bla/BB98–22/
BGR/2008; GU190221 Betacoronavirus Bat coronavi-
rus BR98–19/BGR/2008; GU190222 Betacoronavirus 
Bat coronavirus BM98–01/BGR/2008; GU190223, 
Betacoronavirus Bat coronavirus BM98–13/BGR/2008.
All synthetic RNA used in this study was photometri-
cally quantified.
RNA extraction
RNA was extracted from clinical samples with the 
MagNA Pure 96 system (Roche, Penzberg, Germany) 
and from cell culture supernatants with the viral RNA 
mini kit (QIAGEN, Hilden, Germany).
Real-time reverse-transcription PCR
A 25 μL reaction contained 5 μL of RNA, 12.5 μL of 
2 × reaction buffer provided with the Superscript III 
one step RT-PCR system with Platinum Taq Polymerase 
(Invitrogen, Darmstadt, Germany; containing 0.4 mM 
of each deoxyribont triphosphates (dNTP) and 3.2 mM 
magnesium sulphate), 1 μL of reverse transcriptase/
Taq mixture from the kit, 0.4 μL of a 50 mM magne-
sium sulphate solution (Invitrogen), and 1 μg of nona-
cetylated bovine serum albumin (Roche). Primer and 
probe sequences, as well as optimised concentra-
tions are shown in  Table 1. All oligonucleotides were 
synthesised and provided by Tib-Molbiol (Berlin, 
Table 1
Primers and probes, real-time RT-PCR for 2019 novel coronavirus
Assay/use Oligonucleotide Sequencea Concentrationb
RdRP gene
RdRp_SARSr-F GTGARATGGTCATGTGTGGCGG Use 600 nM per reaction
RdRp_SARSr-P2 FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ
Specific for 2019-nCoV, will not detect 
SARS-CoV. 
 
Use 100 nM per reaction and mix with P1
RdRP_SARSr-P1 FAM-CCAGGTGGWACRTCATCMGGTGATGC-BBQ
Pan Sarbeco-Probe will detect 2019-nCoV, 
SARS-CoV and bat-SARS-related CoVs. 
 
Use 100 nM per reaction and mix with P2
RdRp_SARSr-R CARATGTTAAASACACTATTAGCATA Use 800 nM per reaction
E gene
E_Sarbeco_F ACAGGTACGTTAATAGTTAATAGCGT Use 400 nm per reaction
E_Sarbeco_P1 FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ Use 200 nm per reaction
E_Sarbeco_R ATATTGCAGCAGTACGCACACA Use 400 nm per reaction
N gene
N_Sarbeco_F CACATTGGCACCCGCAATC Use 600 nm per reaction
N_Sarbeco_P FAM-ACTTCCTCAAGGAACAACATTGCCA-BBQ Use 200 nm per reaction
N_Sarbeco_R GAGGAACGAGAAGAGGCTTG Use 800 nm per reaction
a W is A/T; R is G/A; M is A/C; S is G/C. FAM: 6-carboxyfluorescein; BBQ: blackberry quencher.
b Optimised concentrations are given in nanomol per litre (nM) based on the final reaction mix, e.g. 1.5 µL of a 10 µM primer stock solution per 
25 µL total reaction volume yields a final concentration of 600 nM as indicated in the table.
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Germany). Thermal cycling was performed at 55 °C for 
10 min for reverse transcription, followed by 95 °C for 
3 min and then 45 cycles of 95 °C for 15 s, 58 °C for 30 
s. Participating laboratories used either Roche Light 
Cycler 480II or Applied Biosystems ViiA7 instruments 
(Applied Biosystems, Hong Kong, China).
Protocol options and application notes
Laboratories participating in the evaluation used the 
TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher) 
with the same oligonucleotide concentrations and 
cycling conditions. The QIAGEN One-Step RT-PCR Kit 
was also tested and found to be compatible.
The intended cross-reactivity of all assays with viral 
RNA of SARS-CoV allows us to use the assays without 
having to rely on external sources of specific 2019-
nCoV RNA.
For a routine workflow, we recommend the E gene assay 
as the first-line screening tool, followed by confirma-
tory testing with the RdRp gene assay. Application of 
the RdRp gene assay with dual colour technology can 
discriminate 2019-nCoV (both probes positive) from 
SARS-CoV RNA if the latter is used as positive control. 
Alternatively, laboratories may choose to run the RdRp 
assay with only the 2019-nCoV-specific probe.
Ethical statement
The internal use of samples for diagnostic workflow 
optimisation was agreed under the medical ethical 
rules of each of the participating partners.
Results
Before public release of virus sequences from cases of 
2019-nCoV, we relied on social media reports announc-
ing detection of a SARS-like virus. We thus assumed 
that a SARS-related CoV is involved in the outbreak. 
We downloaded all complete and partial (if > 400 nt) 
SARS-related virus sequences available in GenBank by 
1 January 2020. The list (n = 729 entries) was manually 
checked and artificial sequences (laboratory-derived, 
synthetic, etc), as well as sequence duplicates were 
removed, resulting in a final list of 375 sequences. 
These sequences were aligned and the alignment was 
used for assay design (Supplementary Figure S1). Upon 
release of the first 2019-nCoV sequence at virological.
org, three assays were selected based on how well 
they matched to the 2019-nCoV genome (Figure 1). The 
alignment was complemented by additional sequences 
released independently on GISAID (https://www.
gisaid.org), confirming the good matching of selected 
primers to all sequences. Alignments of primer bind-
ing domains with 2019-nCoV, SARS-CoV as well as 
selected bat-associated SARS-related CoV are shown 
in Figure 2.
Assay sensitivity based on SARS coronavirus 
virions
To obtain a preliminary assessment of analytical sen-
sitivity, we used purified cell culture supernatant 
containing SARS-CoV strain Frankfurt-1 virions grown 
on Vero cells. The supernatant was ultrafiltered and 
thereby concentrated from a ca 20-fold volume of cell 
culture supernatant. The concentration step simulta-
neously reduces the relative concentration of back-
ground nucleic acids such as not virion-packaged viral 
RNA. The virion preparation was quantified by real-
time RT-PCR using a specific in vitro-transcribed RNA 
quantification standard as described in Drosten et al. 
[8]. All assays were subjected to replicate testing in 
order to determine stochastic detection frequencies 
at each assay’s sensitivity end point (Figure 3A and 
B). All assays were highly sensitive, with best results 
obtained for the E gene and RdRp gene assays (5.2 and 
3.8 copies per reaction at 95% detection probability, 
respectively). These two assays were chosen for further 
evaluation. One of the laboratories participating in the 
external evaluation used other basic RT-PCR reagents 
(TaqMan Fast Virus 1-Step Master Mix) and repeated 
the sensitivity study, with equivalent results (E gene: 
3.2 RNA copies/reaction (95% CI: 2.2–6.8); RdRP: 3.7 
RNA copies/reaction (95% CI: 2.8–8.0). Of note, the N 
gene assay also performed well but was not subjected 
Figure 1
Relative positions of amplicon targets on the SARS coronavirus and the 2019 novel coronavirus genome
Orf1ab S NMEOrf1a
15,361–15,460
RdRp
NC_004718 SARS-CoV
26,141–26,253
E
28,555–28,682
N
MN908947 W uhan-Hu-1
E: envelope protein gene; M: membrane protein gene; N: nucleocapsid protein gene; ORF: open reading frame; RdRp: RNA-dependent RNA 
polymerase gene; S: spike protein gene.
Numbers below amplicons are genome positions according to SARS-CoV, GenBank NC_004718.
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to intensive further validation because it was slightly 
less sensitive (Supplementary Figure S2)
Sensitivity based on in vitro-transcribed RNA 
identical to 2019 novel coronavirus target 
sequences
Although both assays detected 2019-nCoV without 
polymorphisms at oligonucleotide binding sites (Figure 
2), we additionally generated in vitro-transcribed RNA 
standards that exactly matched the sequence of 2019-
nCoV for absolute quantification and studying the limit 
of detection (LOD). Replicate reactions were done at 
concentrations around the detection end point deter-
mined in preliminary dilution experiments. The result-
ing LOD from replicate tests was 3.9 copies per reaction 
for the E gene assay and 3.6 copies per reaction for the 
RdRp assay (Figure 3C and D). These figures were close 
to the 95% hit rate of 2.9 copies per reaction, according 
to the Poisson distribution, expected when one RNA 
molecule is detected.
Discrimination of 2019 novel coronavirus from 
SARS coronavirus by RdRp assay
Following the rationale that SARS-CoV RNA can be 
used as a positive control for the entire laboratory pro-
cedure, thus obviating the need to handle 2019-nCoV 
RNA, we formulated the RdRp assay so that it contains 
two probes: a broad-range probe reacting with SARS-
CoV and 2019-nCoV and an additional probe that reacts 
only with 2019-nCoV. By limiting dilution experiments, 
we confirmed that both probes, whether used indi-
vidually or in combination, provided the same LOD for 
each target virus. The specific probe RdRP_SARSr-P2 
detected only the 2019-nCoV RNA transcript but not the 
SARS-CoV RNA.
Detection range for SARS-related 
coronaviruses from bats
At present, the potential exposure to a common envi-
ronmental source in early reported cases implicates 
the possibility of independent zoonotic infections with 
increased sequence variability [5]. To show that the 
assays can detect other bat-associated SARS-related 
viruses, we used the E gene assay to test six bat-
derived faecal samples available from Drexler et al. 
[13] und Muth et al. [14]. These virus-positive samples 
stemmed from European rhinolophid bats. Detection 
of these phylogenetic outliers within the SARS-related 
CoV clade suggests that all Asian viruses are likely to 
be detected. This would, theoretically, ensure broad 
sensitivity even in case of multiple independent acqui-
sitions of variant viruses from an animal reservoir.
Specificity testing
Chemical stability
To exclude non-specific reactivity of oligonucleo-
tides among each other, causing artificial fluorescent 
Figure 2
Partial alignments of oligonucleotide binding regions, SARS-related coronaviruses (n = 9)
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RdRP_SARSr-P2
P1:
P2:
A. RdRp gene
B. E gene
C. N gene
N_Sarbeco_F N_Sarbeco_P N_Sarbeco_R
E_Sarbeco_F E_Sarbeco_P1 E_Sarbeco_R
RdR _p SARSr-F
RdR _p rSARS -
RdR _p SARSr-R
The panels show six available sequences of 2019-nCoV, aligned to the corresponding partial sequences of SARS-CoV strain Frankfurt 1, 
which can be used as a positive control for all three RT-PCR assays. The alignment also contains a closely related bat virus (Bat SARS-related 
CoV isolate bat-SL-CoVZC45, GenBank accession number MG772933) as well as the most distant member within the SARS-related bat CoV 
clade, detected in Bulgaria (GenBank accession number NC_014470). Dots represent identical nucleotides compared with the WH_Human_1 
sequence. Nucleotide substitutions are specified. Blue arrows: oligonucleotides as specified in Table 1. More comprehensive alignments can 
be found in the Supplement.
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Figure 3
Determination of limits of detection based on SARS coronavirus genomic RNA and 2019 novel coronavirus-specific in vitro 
transcribed RNA
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CI: confidence intervals; c/r: copies per reaction; IVT: in vitro-transcribed RNA.
A: E gene assay, evaluated with SARS-CoV genomic RNA. B: RdRp gene assay evaluated with SARS-CoV genomic RNA. C: E-gene assay, 
evaluated with 2019-nCoV-specific in vitro-transcribed RNA standard. D: RdRp gene assay evaluated with 2019-nCoV-specific in vitro-
transcribed RNA standard.
The x-axis shows input RNA copies per reaction. The y-axis shows positive results in all parallel reactions performed, squares are 
experimental data points resulting from replicate testing of given concentrations (x-axis) in parallels assays (eight replicate reactions per 
point).
Technical limits of detection are given in the panels headings. The inner line is a probit curve (dose-response rule). The outer dotted lines are 
95% CI.
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signals, all assays were tested 120 times in parallel 
with water and no other nucleic acid except the pro-
vided oligonucleotides. In none of these reactions was 
any positive signal detected.
Cross-reactivity with other coronaviruses
Cell culture supernatants containing all endemic human 
coronaviruses (HCoV)229E, NL63, OC43 and HKU1 as 
well as MERS-CoV were tested in duplicate in all three 
assays (Table 2). For the non-cultivable HCoV-HKU1, 
supernatant from human airway culture was used. Viral 
RNA concentration in all samples was determined by 
specific real-time RT-PCRs and in vitro-transcribed RNA 
standards designed for absolute quantification of viral 
load. Additional undiluted (but not quantified) cell cul-
ture supernatants were tested as summarised in Table 
2. These were additionally mixed into negative human 
sputum samples. None of the tested viruses or virus 
preparations showed reactivity with any assay.
Exclusivity of 2019 novel coronavirus based on clinical 
samples pre-tested positive for other respiratory viruses
Using the E and RdRp gene assays, we tested a total 
of 297 clinical samples from patients with respiratory 
disease from the biobanks of five laboratories that 
provide diagnostic services (one in Germany, two in 
the Netherlands, one in Hong Kong, one in the UK). We 
selected 198 samples from three university medical 
centres where patients from general and intensive care 
wards as well as mainly paediatric outpatient depart-
ments are seen (Germany, the Netherlands, Hong 
Kong). The remaining samples were contributed by 
national public health services performing surveillance 
studies (RIVM, PHE), with samples mainly submitted 
by practitioners. The samples contained the broadest 
range of respiratory agents possible and reflected the 
general spectrum of virus concentrations encountered 
in diagnostic laboratories in these countries (Table 2). 
In total, this testing yielded no false positive outcomes. 
In four individual test reactions, weak initial reactivity 
was seen but they were negative upon retesting with 
the same assay. These signals were not associated 
with any particular virus, and for each virus with which 
initial positive reactivity occurred, there were other 
samples that contained the same virus at a higher con-
centration but did not test positive. Given the results 
from the extensive technical qualification described 
above, it was concluded that this initial reactivity was 
not due to chemical instability of real-time PCR probes 
but most probably to handling issues caused by the 
rapid introduction of new diagnostic tests and controls 
during this evaluation study.
Discussion
The present report describes the establishment of a 
diagnostic workflow for detection of an emerging virus 
in the absence of physical sources of viral genomic 
nucleic acid. Effective assay design was enabled by the 
willingness of scientists from China to share genome 
information before formal publication, as well as the 
availability of broad sequence knowledge from ca 15 
years of investigation of SARS-related viruses in animal 
reservoirs. The relative ease with which assays could 
be designed for this virus, in contrast to SARS-CoV in 
2003, proves the huge collective value of descriptive 
studies of disease ecology and viral genome diversity 
[8,15-17].
Real-time RT-PCR is widely deployed in diagnostic virol-
ogy. In the case of a public health emergency, profi-
cient diagnostic laboratories can rely on this robust 
technology to establish new diagnostic tests within 
their routine services before pre-formulated assays 
become available. In addition to information on 
Table 2
Tests of known respiratory viruses and bacteria in clinical 
samples and cell culture preparations for cross-reactivity 
in 2019 novel coronavirus E and RdRp gene assays (n = 
310)
Clinical samples with known 
viruses
Clinical 
samplesa
Virus 
isolatesb
HCoV-HKU1 14 1c
HCoV-OC43 16 2d
HCoV-NL63 14 1e
HCoV-229E 18 2f
MERS-CoV 5 1g
Influenza A(H1N1)pdm09 17 1
Influenza A(H3N2) 16 1
Influenza A (untyped) 11 NA
Influenza A(H5N1) 1 1
Influenza A(H7N9) 0 1
Influenza B (Victoria or 
Yamagata) 31 1
Rhinovirus/enterovirus 31 NA
Respiratory syncytial virus (A/B) 33 NA
Parainfluenza 1 virus 12 NA
Parainfluenza 2 virus 11 NA
Parainfluenza 3 virus 14 NA
Parainfluenza 4 virus 11 NA
Human metapneumovirus 16 NA
Adenovirus 13 1
Human bocavirus 6 NA
Legionella spp. 3 NA
Mycoplasma spp. 4 NA
Total clinical samples 297 NA
a For samples with multiple viruses detected, the virus with highest 
concentration is listed, as indicated by real-time PCR Ct value.
b Directly quantified or spiked in human negative-testing sputum.
c 1 × 105 RNA copies/mL, determined by specific real-time RT-PCR. 
Isolated from human airway epithelial culture.
d 1 × 1010 RNA copies/mL, determined by specific real-time RT-PCR 
of one isolate. The other isolate was not quantified but spiked in 
human negative-testing sputum.
e 4 × 109 RNA copies/mL, determined by specific real-time RT-PCR.
f 3 × 109 RNA copies/mL, determined by specific real-time RT-PCR 
of one isolate. The other isolate was not quantified spiked in 
human negative-testing sputum.
g 1 × 108 RNA copies/mL, determined by specific real-time RT-PCR.
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reagents, oligonucleotides and positive controls, lab-
oratories working under quality control programmes 
need to rely on documentation of technical qualifi-
cation of the assay formulation as well as data from 
external clinical evaluation tests. The provision of con-
trol RNA templates has been effectively implemented 
by the EVAg project that provides virus-related rea-
gents from academic research collections [18]. SARS-
CoV RNA was retrievable from EVAg before the present 
outbreak; specific products such as RNA transcripts 
for the here-described assays were first retrievable 
from the EVAg online catalogue on 14 January 2020 
(https://www.european-virus-archive.com). Technical 
qualification data based on cell culture materials and 
synthetic constructs, as well as results from exclusiv-
ity testing on 75 clinical samples, were included in the 
first version of the diagnostic protocol provided to the 
WHO on 13 January 2020. Based on efficient collabo-
ration in an informal network of laboratories, these 
data were augmented within 1 week comprise testing 
results based on a wide range of respiratory pathogens 
in clinical samples from natural infections. Comparable 
evaluation studies during regulatory qualification of in 
vitro diagnostic assays can take months for organisa-
tion, legal implementation and logistics and typically 
come after the peak of an outbreak has waned. The 
speed and effectiveness of the present deployment 
and evaluation effort were enabled by national and 
European research networks established in response 
to international health crises in recent years, demon-
strating the enormous response capacity that can be 
released through coordinated action of academic and 
public laboratories [18-22]. This laboratory capacity not 
only supports immediate public health interventions 
but enables sites to enrol patients during rapid clinical 
research responses.
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